M&A · Healthcare · Buyer's industry: Biological Products, (No Diagnostic Substances)
Repligen Corp to acquire Metenova
Announced Sep 26, 2023 · Closed Oct 2, 2023 · Private target
Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationCash and stock
Transaction
- Acquirer
- Repligen Corp (RGEN)
- Target
- Metenova
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed Oct 2, 2023
Deal protections
Not disclosed for private-company acquisitions.
Advisors
- To the acquirer
- Perella Weinberg
- To the target
- Not disclosed
Classification
- Sector
- Healthcare
- Buyer's industry
- Biological Products, (No Diagnostic Substances)